Cervical Cancer Metastatic

Also known as: Metastatic Cervical Cancers / Metastatic Cervical Cancer

DrugDrug NameDrug Description
DB00112BevacizumabA monoclonal anti-vascular endothelial growth factor antibody used in combination with antineoplastic agents for the treatment of many types of cancer.
DB14707CemiplimabA programmed death receptor-1 blocking antibody used to treat cutaneous squamous cell carcinoma, basal cell carcinoma, and non-small cell lung cancer.
DB00762IrinotecanA topoisomerase inhibitor used to treat metastatic carcinoma of the colon or rectum and pancreatic adenocarcinoma.
DB09037PembrolizumabA PD-1 blocking antibody used to treat various types of cancer, including metastatic melanoma, non small-cell lung cancer, cervical cancer, head and neck cancer, and Hodgkin's lymphoma.
DB00642PemetrexedA folate analog used to treat mesothelioma and non-small cell lung cancer.
DB16732Tisotumab vedotinA tissue factor-directed antibody drug conjugate that is used to treat adults with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.
DB00361VinorelbineA vinca alkaloid used in the treatment of metastatic non-small cell lung carcinoma (NSLC) and in conjunction with other drugs in locally advanced NSCLC.
DrugDrug NameTargetType
DB00112BevacizumabVascular endothelial growth factor Atarget
DB00112BevacizumabComplement C1q subcomponent subunit Atarget
DB00112BevacizumabComplement C1q subcomponent subunit Btarget
DB00112BevacizumabComplement C1q subcomponent subunit Ctarget
DB00112BevacizumabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB00112BevacizumabLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB00112BevacizumabLow affinity immunoglobulin gamma Fc region receptor II-btarget
DB00112BevacizumabLow affinity immunoglobulin gamma Fc region receptor II-ctarget
DB00112BevacizumabHigh affinity immunoglobulin gamma Fc receptor Itarget
DB14707CemiplimabProgrammed cell death protein 1target
DB00762IrinotecanDNA topoisomerase I, mitochondrialtarget
DB00762IrinotecanDNA topoisomerase 1target
DB00762IrinotecanCytochrome P450 3A4enzyme
DB00762IrinotecanCytochrome P450 3A5enzyme
DB00762IrinotecanUDP-glucuronosyltransferase 1-1enzyme
DB00762IrinotecanUDP-glucuronosyltransferase 1-9enzyme
DB00762IrinotecanCytochrome P450 3A7enzyme
DB00762IrinotecanSolute carrier family 22 member 3transporter
DB00762IrinotecanSolute carrier organic anion transporter family member 1B1transporter
DB00762IrinotecanMultidrug resistance-associated protein 1transporter
DB00762IrinotecanATP-binding cassette sub-family G member 2transporter
DB00762IrinotecanSerum albumincarrier
DB00762IrinotecanP-glycoprotein 1transporter
DB00762IrinotecanCanalicular multispecific organic anion transporter 1transporter
DB00762IrinotecanHuman Carboxylesterasesenzyme
DB09037PembrolizumabProgrammed cell death protein 1target
DB09037PembrolizumabProgrammed cell death 1 ligand 1target
DB00642PemetrexedThymidylate synthasetarget
DB00642PemetrexedDihydrofolate reductasetarget
DB00642PemetrexedTrifunctional purine biosynthetic protein adenosine-3target
DB00642PemetrexedDeoxycytidine kinaseenzyme
DB00642PemetrexedBifunctional purine biosynthesis protein PURHtarget
DB00642PemetrexedEquilibrative nucleoside transporter 1enzyme
DB00642PemetrexedSolute carrier family 22 member 8transporter
DB00642PemetrexedFolate transporter 1transporter
DB00642PemetrexedProton-coupled folate transportertransporter
DB00642PemetrexedATP-binding cassette sub-family G member 2transporter
DB00642PemetrexedMultidrug resistance-associated protein 5transporter
DB00642PemetrexedSolute carrier family 22 member 6transporter
DB00642PemetrexedSerum albumincarrier
DB00642PemetrexedSolute carrier family 22 member 11transporter
DB16732Tisotumab vedotinCytochrome P450 3A4enzyme
DB16732Tisotumab vedotinTissue factortarget
DB16732Tisotumab vedotinP-glycoprotein 1transporter
DB00361VinorelbineTubulin beta chaintarget
DB00361VinorelbineCytochrome P450 3A4enzyme
DB00361VinorelbineCytochrome P450 2D6enzyme
DrugDrug NamePhaseStatusCount
DB11714Durvalumab1Terminated1
DB11771Tremelimumab1Terminated1
DB11595Atezolizumab2Recruiting1
DB00112Bevacizumab2Unknown Status1
DB08875Cabozantinib2Terminated1
DB16680Cadonilimab2Completed1
DB14776Camrelizumab2Completed1
DB00958Carboplatin2Unknown Status1
DB00515Cisplatin2Unknown Status1
DB16372Cobolimab2Recruiting1
DB15627Dostarlimab2Recruiting1
DB01259Lapatinib2Completed1
DB09078Lenvatinib2Recruiting1
DB01229Paclitaxel2Unknown Status1
DB06589Pazopanib2Completed1
DB09037Pembrolizumab2Recruiting1
DB09037Pembrolizumab2Terminated1
DB14765Rivoceranib2Completed1
DB15036Sitravatinib2Withdrawn1
DB14922Tislelizumab2Withdrawn1
DB15676Balstilimab3Withdrawn1
DB00958Carboplatin3Recruiting1
DB00515Cisplatin3Recruiting1
DB00441Gemcitabine3Withdrawn1
DB01275Hydralazine3Unknown Status1
DB00762Irinotecan3Withdrawn1
DB01229Paclitaxel3Recruiting1
DB00642Pemetrexed3Withdrawn1
DB17562QL17063Recruiting1
DB01030Topotecan3Withdrawn1
DB00313Valproic acid3Unknown Status1
DB00361Vinorelbine3Withdrawn1
DB00112BevacizumabNot AvailableRecruiting1